Please read these Terms of Use carefully before accessing or using any part of the Web Site. All users of the Web Site are subject to the following website terms and conditions of use (these “Terms of Use”). If you are accessing the Web Site from outside the United States, Canada, or Puerto Rico, please see the appropriate international website, available at for applicable terms and conditions. These terms and conditions of use are applicable to the United States, Canada and Puerto Rico websites (“collectively the Web Site”) operated by VWR (the “Company”). HALO® Chromatography Columns and Consumables+. Sartorius laboratory instruments, consumables and services PerkinElmer - Innovating for a Healthier World ![]() Lab Thermometers & Temperature Measurement EquipmentĪgilent Chemistries and Supplies Portfolio Quality Products from Sheldon Manufacturing Life Science Research Solutions, Products, and Resources VWR will support you from the latest life science products to the guaranteed purity of organic building blocks. Their success demonstrates that mutual benefits can be achieved when suppliers and manufacturers work together to advance innovation and usher in a new era of drug development.A strong, vibrant research and development group is the lifeblood of all industries. Supplier and bio-manufacturer relationships are often treated as transactional ones yet, through this collaboration, Cobra and Cytiva were able to combine their expertise and experience and create a solution to address this manufacturing constraint. The resin was developed based on Cobra’s need but made available as product for others to order. Working with Cytiva, the companies developed a next-generation chromatography resin for the purification of plasmid DNA to reduce development costs and increase the manufacturing capacity through increased plasmid batch size and facility throughput. ![]() CDMO Cobra Biologics recognized the need to address its own plasmid DNA capacity constraints for the rapidly increasing demand for viral vector production by not only increasing physical capacity but also by reexamining the purification process currently being used. This has led to pressure on manufacturers to create the capacity and resources essential to meeting the rising demand for high quality plasmid DNA. As products progress through clinical phases, there is a greater need for scalable plasmid DNA production, which must first be manufactured and purified in a GMP facility or high-quality plasmid DNA production areas. The vehicle for the delivery of these therapies is the viral vector, with adeno-associated viruses (AAV) being the most notable ones, as they have proven to be safe in humans while also exhibiting low immunogenicity.ĪAV and lentiviral vectors are commonly produced through transfection with plasmid DNA containing the gene of interest. The ability to use the unique capabilities of RNA and DNA viruses to deliver functional genes in place of defective ones has led to the pursuit and development of a substantial number of cell and gene therapies. The rapid growth of the cell and gene therapy market is creating exciting opportunities in the advanced therapy sector. By Janice Charlesworth, Downstream Processing Leader, Cobra Biologics Tony Hitchcock, Technical Director, Cobra Biologics Hazel Tharia, Head of Technical Co-ordination, Cobra Biologics Henrik Ihre, Global Strategic Customer Relations Director, Cytiva and Åsa Hagner McWhirter, Senior Application Scientist, Cytiva
0 Comments
Leave a Reply. |